Recent studies have identified several biomarkers that can predict the efficacy of immunotherapy, including familiar PD-L1 overexpression, microsatellite instability (MSI), and tumor mutation burden (TMB) (Chan et al., 2019; Doroshow et al., 2021; Kwon et al., 2021). Here, CD274 is linked to neoplasm.